February 9, 2022 10:56 AM EST
News Briefing

Bio­Marin lands $110m sale of pri­or­i­ty re­view vouch­er; Hy­bridize li­cens­es out BK virus ther­a­py

Josh Sullivan

Bio­Marin an­nounced that it has sold its pri­or­i­ty re­view vouch­er for $110 mil­lion, but it hasn’t an­nounced who the buy­er is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times